170 related articles for article (PubMed ID: 1504053)
1. Rapid cytokine release in cancer patients treated with interleukin-2.
Weidmann E; Bergmann L; Stock J; Kirsten R; Mitrou PS
J Immunother (1991); 1992 Aug; 12(2):123-31. PubMed ID: 1504053
[TBL] [Abstract][Full Text] [Related]
2. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
3. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
4. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
Finck-Seelen ; Lampert R; Brandt L
Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
[TBL] [Abstract][Full Text] [Related]
5. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants.
McIntyre CA; Chapman K; Reeder S; Dorreen MS; Bruce L; Rodgers S; Hayat K; Schreenivasan T; Sheridan E; Hancock BW
Eur J Cancer; 1992; 28(1):58-63. PubMed ID: 1567693
[TBL] [Abstract][Full Text] [Related]
6. Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2.
Miles D; Thomsen L; Balkwill F; Thavasu P; Moncada S
Eur J Clin Invest; 1994 Apr; 24(4):287-90. PubMed ID: 8050458
[TBL] [Abstract][Full Text] [Related]
7. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
8. Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2.
Eskander ED; Harvey HA; Givant E; Lipton A
Am J Clin Oncol; 1997 Oct; 20(5):511-4. PubMed ID: 9345339
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium.
Salvo G; Samoggia P; Masciulli R; Boccoli G; Allavena P; Mariani G; Bullo A; Montesoro E; Bulgarini D; Carlini P
Eur J Cancer; 1992; 28A(4-5):818-25. PubMed ID: 1524901
[TBL] [Abstract][Full Text] [Related]
10. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Merad M; Angevin E; Wolfers J; Flament C; Lorenzi I; Triebel F; Escudier B; Zitvogel L
J Immunother; 2000; 23(3):369-78. PubMed ID: 10838666
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
12. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.
Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP
Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818
[TBL] [Abstract][Full Text] [Related]
13. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
[TBL] [Abstract][Full Text] [Related]
14. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
15. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation.
Heslop HE; Gottlieb DJ; Bianchi AC; Meager A; Prentice HG; Mehta AB; Hoffbrand AV; Brenner MK
Blood; 1989 Sep; 74(4):1374-80. PubMed ID: 2504308
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
[TBL] [Abstract][Full Text] [Related]
17. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
19. Whole body energy expenditure protein breakdown and polyamine excretion during high dose treatment with interleukin-2 and interferon-alpha.
Naredi P; Hafström L; Zachrisson H; Rudenstam CM; Lundholm K
Eur J Surg; 1994 Feb; 160(2):67-75. PubMed ID: 8193211
[TBL] [Abstract][Full Text] [Related]
20. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
